Narcolepsy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Narcolepsy – Drugs In Development, 2024 report and make more profitable business decisions.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling.
The Narcolepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Narcolepsy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Narcolepsy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Narcolepsy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Narcolepsy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aculys Pharma LLCAexon Labs Inc
Axsome Therapeutics Inc
Bioprojet SCR
Centessa Pharmaceuticals Plc
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Gubra ApS
Harmony Biosciences Holdings Inc
Inexia Ltd
Jazz Pharmaceuticals Plc
Lennham Pharmaceuticals Inc
NLS Pharmaceutics AG
Seelos Therapeutics
Inc.
Sumitomo Pharma Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Synchronicity Pharma Inc
Takeda Pharmaceutical Co Ltd
Tris Pharma Inc
University of Tsukuba
XWPharma Ltd
Zevra Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Narcolepsy reports